Table 1 The therapeutic effects of hAMSCs on patients’ GCs with premature ovarian failure [68]
From: Human mesenchymal stem cell treatment of premature ovarian failure: new challenges and opportunities
|  | DOR (n = 29) | POF (n = 36) | ||||
|---|---|---|---|---|---|---|
Control | hAMSCs | P value | Control | hAMSCs | P value | |
No. of AMH cell | 22% | 83% | < 0.01 | 4.5% | 45% | < 0.01 |
No. of FSHR cell | 41% | 84% | < 0.01 | 17% | 51% | < 0.01 |
No. Of FOXL2 cell | 34% | 88% | < 0.01 | 19% | 70% | < 0.01 |
No. of CYP19A1 cell | 45% | 92% | < 0.01 | 34% | 81% | < 0.01 |